Brief: Achieve Life Sciences Announces Last Subject Dosed In Phase 2 ORCA-V1 Trial Of Cytisinicline For E-Cigarette Cessation
07/02/2023 13:05
Feb 7 (Reuters) - Achieve Life Sciences Inc ACHV.O :
* ACHIEVE LIFE SCIENCES ANNOUNCES LAST SUBJECT DOSED IN
PHASE 2
ORCA-V1 TRIAL OF CYTISINICLINE FOR E-CIGARETTE CESSATION
* ACHIEVE LIFE SCIENCES ANNOUNCES LAST SUBJECT DOSED IN
PHASE 2
ORCA-V1 TRIAL OF CYTISINICLINE FOR E-CIGARETTE CESSATION
Source text for Eikon: ID:nGNX51GRVw
Further company coverage: ACHV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock